Cytek BiosciencesCTKB +0.80%71 5-Year ROIIC % is -41.00 as of Dec. 2025. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.82 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 734 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 80.79% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Cytek Biosciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was -41.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cytek Biosciences's 5-Year ROIIC % or its related term are showing as below:
CTKB's 5-Year ROIIC % is ranked worse than 80.79% of 734
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs CTKB: -41.00
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cytek Biosciences 5-Year ROIIC % Related Terms
Cytek Biosciences 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, NPCE, CLPT: 5-Year ROIIC % Comparison
For the Medical Devices subindustry, Cytek Biosciences's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's 5-Year ROIIC % falls into.
Cytek Biosciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -40.384 (Dec. 2025) - 13.659 (Dec. 2020) )
/
( 179.095 (Dec. 2025) - 47.285 (Dec. 2020) )
=
-54.043
/
131.81
=
-41.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cytek Biosciences (CTKB) has a 5-Year ROIIC % of -41.00 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Cytek Biosciences and its competitors. According to the industry distribution chart, Cytek Biosciences ranks #593 out of 734 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is Cytek Biosciences' 5-Year ROIIC % too high?
Cytek Biosciences' current 5-Year ROIIC % is -41.00. Based on the distribution chart, Cytek Biosciences ranks #593 out of 734 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' 5-Year ROIIC % compare to CERS and NPCE?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #593 out of 734 companies for 5-Year ROIIC %. This places Cytek Biosciences in the lower half of its industry. The industry median 5-Year ROIIC % is 0.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.95, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current 5-Year ROIIC % is -41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.82, compared to a current price of $4.39 — trading 24.7% below its estimated fair value. The current 5-Year ROIIC % is -41.00. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current 5-Year ROIIC % is -41.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.39 is trading 24.7% below its estimated GF Value™ of $5.82.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
5-Year ROIIC %: -41.00
GF Value™: $5.82 vs. price of $4.39 (24.7% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
